Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Dec;85(12):1937–1943. doi: 10.1054/bjoc.2001.2175

Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma

N A C S Wong 1, L Brett 1, M Stewart 2, A Leitch 3, D B Longley 4, M G Dunlop 3, P G Johnston 4, A M Lessells 1, D I Jodrell 2
PMCID: PMC2364004  PMID: 11747337

Abstract

Thymidylate synthase (TS) is a key enzyme in DNA synthesis and is inhibited by metabolites of the chemotherapeutic agent 5-fluorouracil (5FU). Nuclear expression of TS in human tissue in vivo has not been characterised and its clinicopathological correlates in malignancy are unknown. 52 cases of primary colorectal carcinoma (CRC) and 24 cases of matched metastatic carcinoma were studied immunohistochemically using the monoclonal antibody TS106. The degree of nuclear TS immunostaining correlated closely with levels of TS mRNA expression amongst 10 CRCs studied. Strong nuclear immunostaining was seen in normal basal crypt colonocytes and germinal centre cells, and in a varying proportion of adenocarcinoma cells. Amongst the primary carcinomas, higher TS nuclear expression was associated with prominent extracellular mucin production and right-sided location. Higher TS nuclear expression also showed a significant association with poorer response to protracted venous infusional 5FU therapy. There was no clear association between TS nuclear expression and Ki67 or p53 expression assessed immunohistochemically. There was a strong positive correlation between TS nuclear expression in primary and metastatic CRC but the latter generally showed higher expression than matched primary tumour tissue. These findings confirm the nuclear expression of TS protein in human cells in vivo and provide new insight into how such expression may relate to the behaviour of CRCs. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: thymidylate synthase, colorectal carcinoma, immunohistochemistry, 5-fluorouracil, p53 protein, metastases

Full Text

The Full Text of this article is available as a PDF (121.0 KB).

Footnotes

Data from this study were presented at the 179th Meeting of the Pathological Society of Great Britain and Ireland, held at Ninewells Hospital & Medical School, Dundee, UK.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aschele C., Debernardis D., Casazza S., Antonelli G., Tunesi G., Baldo C., Lionetto R., Maley F., Sobrero A. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol. 1999 Jun;17(6):1760–1770. doi: 10.1200/JCO.1999.17.6.1760. [DOI] [PubMed] [Google Scholar]
  2. Aschele C., Debernardis D., Tunesi G., Maley F., Sobrero A. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res. 2000 Dec;6(12):4797–4802. [PubMed] [Google Scholar]
  3. Bikfalvi A. Significance of angiogenesis in tumour progression and metastasis. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1101–1104. doi: 10.1016/0959-8049(95)00169-j. [DOI] [PubMed] [Google Scholar]
  4. Brett M. C., Pickard M., Green B., Howel-Evans A., Smith D., Kinsella A., Poston G. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol. 1996 Apr;22(2):182–185. doi: 10.1016/s0748-7983(96)90827-6. [DOI] [PubMed] [Google Scholar]
  5. Carethers J. M., Chauhan D. P., Fink D., Nebel S., Bresalier R. S., Howell S. B., Boland C. R. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology. 1999 Jul;117(1):123–131. doi: 10.1016/s0016-5085(99)70558-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chu E., Cogliati T., Copur S. M., Borre A., Voeller D. M., Allegra C. J., Segal S. Identification of in vivo target RNA sequences bound by thymidylate synthase. Nucleic Acids Res. 1996 Aug 15;24(16):3222–3228. doi: 10.1093/nar/24.16.3222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chu E., Copur S. M., Ju J., Chen T. M., Khleif S., Voeller D. M., Mizunuma N., Patel M., Maley G. F., Maley F. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol. 1999 Feb;19(2):1582–1594. doi: 10.1128/mcb.19.2.1582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. De Both N. J., Vermey M., Groen N., Dinjens W. N., Bosman F. T. Clonal growth of colorectal-carcinoma cell lines transplanted to nude mice. Int J Cancer. 1997 Sep 17;72(6):1137–1141. doi: 10.1002/(sici)1097-0215(19970917)72:6<1137::aid-ijc32>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  9. Edler D., Blomgren H., Allegra C. J., Johnston P. G., Lagerstedt U., Magnusson I., Ragnhammar P. Immunohistochemical determination of thymidylate synthase in colorectal cancer--methodological studies. Eur J Cancer. 1997 Nov;33(13):2278–2281. doi: 10.1016/s0959-8049(97)00306-7. [DOI] [PubMed] [Google Scholar]
  10. Elsaleh H., Joseph D., Grieu F., Zeps N., Spry N., Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 2000 May 20;355(9217):1745–1750. doi: 10.1016/S0140-6736(00)02261-3. [DOI] [PubMed] [Google Scholar]
  11. Findlay M. P., Cunningham D., Morgan G., Clinton S., Hardcastle A., Aherne G. W. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer. 1997;75(6):903–909. doi: 10.1038/bjc.1997.159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hemminki A., Mecklin J. P., Järvinen H., Aaltonen L. A., Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology. 2000 Oct;119(4):921–928. doi: 10.1053/gast.2000.18161. [DOI] [PubMed] [Google Scholar]
  13. Horikoshi T., Danenberg K. D., Stadlbauer T. H., Volkenandt M., Shea L. C., Aigner K., Gustavsson B., Leichman L., Frösing R., Ray M. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res. 1992 Jan 1;52(1):108–116. [PubMed] [Google Scholar]
  14. Jodrell D. I., Stewart M., Aird R., Knowles G., Bowman A., Wall L., McLean C. 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer. Br J Cancer. 2001 Mar 2;84(5):600–603. doi: 10.1054/bjoc.2000.1664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Johnston P. G., Fisher E. R., Rockette H. E., Fisher B., Wolmark N., Drake J. C., Chabner B. A., Allegra C. J. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol. 1994 Dec;12(12):2640–2647. doi: 10.1200/JCO.1994.12.12.2640. [DOI] [PubMed] [Google Scholar]
  16. Johnston P. G., Lenz H. J., Leichman C. G., Danenberg K. D., Allegra C. J., Danenberg P. V., Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995 Apr 1;55(7):1407–1412. [PubMed] [Google Scholar]
  17. Johnston P. G., Liang C. M., Henry S., Chabner B. A., Allegra C. J. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res. 1991 Dec 15;51(24):6668–6676. [PubMed] [Google Scholar]
  18. Lee Y., Chen Y., Chang L. S., Johnson L. F. Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein. Exp Cell Res. 1997 Aug 1;234(2):270–276. doi: 10.1006/excr.1997.3605. [DOI] [PubMed] [Google Scholar]
  19. Leichman L., Lenz H. J., Leichman C. G., Groshen S., Danenberg K., Baranda J., Spears C. P., Boswell W., Silberman H., Ortega A. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1306–1310. doi: 10.1016/0959-8049(95)00326-e. [DOI] [PubMed] [Google Scholar]
  20. Lenz H. J., Danenberg K. D., Leichman C. G., Florentine B., Johnston P. G., Groshen S., Zhou L., Xiong Y. P., Danenberg P. V., Leichman L. P. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res. 1998 May;4(5):1227–1234. [PubMed] [Google Scholar]
  21. Lenz H. J., Hayashi K., Salonga D., Danenberg K. D., Danenberg P. V., Metzger R., Banerjee D., Bertino J. R., Groshen S., Leichman L. P. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res. 1998 May;4(5):1243–1250. [PubMed] [Google Scholar]
  22. McCarty K. S., Jr, Miller L. S., Cox E. B., Konrath J., McCarty K. S., Sr Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985 Aug;109(8):716–721. [PubMed] [Google Scholar]
  23. Paradiso A., Simone G., Petroni S., Leone B., Vallejo C., Lacava J., Romero A., Machiavelli M., De Lena M., Allegra C. J. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer. 2000 Feb;82(3):560–567. doi: 10.1054/bjoc.1999.0964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Peters G. J., van der Wilt C. L., van Groeningen C. J., Smid K., Meijer S., Pinedo H. M. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol. 1994 Oct;12(10):2035–2042. doi: 10.1200/JCO.1994.12.10.2035. [DOI] [PubMed] [Google Scholar]
  25. Peters G. J., van der Wilt C. L., van Triest B., Codacci-Pisanelli G., Johnston P. G., van Groeningen C. J., Pinedo H. M. Thymidylate synthase and drug resistance. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1299–1305. doi: 10.1016/0959-8049(95)00172-f. [DOI] [PubMed] [Google Scholar]
  26. Poon P. P., Storms R. K. Thymidylate synthase is localized to the nuclear periphery in the yeast Saccharomyces cerevisiae. J Biol Chem. 1994 Mar 18;269(11):8341–8347. [PubMed] [Google Scholar]
  27. Ravaioli A., Bagli L., Zucchini A., Monti F. Prognosis and prediction of response in breast cancer: the current role of the main biological markers. Cell Prolif. 1998 Jun-Aug;31(3-4):113–126. doi: 10.1046/j.1365-2184.1998.t01-1-00114.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rhee M. S., Balinska M., Bunni M., Priest D. G., Maley G. F., Maley F., Galivan J. Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells. Cancer Res. 1990 Jul 1;50(13):3979–3984. [PubMed] [Google Scholar]
  29. Révillion F., Pawlowski V., Hornez L., Peyrat J. P. Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. Eur J Cancer. 2000 May;36(8):1038–1042. doi: 10.1016/s0959-8049(00)00051-4. [DOI] [PubMed] [Google Scholar]
  30. Salonga D., Danenberg K. D., Johnson M., Metzger R., Groshen S., Tsao-Wei D. D., Lenz H. J., Leichman C. G., Leichman L., Diasio R. B. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000 Apr;6(4):1322–1327. [PubMed] [Google Scholar]
  31. Samsonoff W. A., Reston J., McKee M., O'Connor B., Galivan J., Maley G., Maley F. Intracellular location of thymidylate synthase and its state of phosphorylation. J Biol Chem. 1997 May 16;272(20):13281–13285. doi: 10.1074/jbc.272.20.13281. [DOI] [PubMed] [Google Scholar]
  32. Sanguedolce R., Vultaggio G., Sanguedolce F., Modica G., Li Volsi F., Diana G., Guereio G., Bellanca L., Rausa L. The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res. 1998 May-Jun;18(3A):1515–1520. [PubMed] [Google Scholar]
  33. Suzuki M., Okabe H., Tsukagoshi S., Kawai T., Fukushima M., Sato I. Immunohistochemical investigation of thymidylate synthase in cervical cancer. Oncology. 1998 Nov-Dec;55(6):564–568. doi: 10.1159/000011913. [DOI] [PubMed] [Google Scholar]
  34. Thomas D. M., Zalcberg J. R. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol. 1998 Nov;25(11):887–895. doi: 10.1111/j.1440-1681.1998.tb02339.x. [DOI] [PubMed] [Google Scholar]
  35. Toft N. J., Arends M. J. DNA mismatch repair and colorectal cancer. J Pathol. 1998 Jun;185(2):123–129. doi: 10.1002/(SICI)1096-9896(199806)185:2<123::AID-PATH62>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  36. Yamachika T., Nakanishi H., Inada K., Tsukamoto T., Kato T., Fukushima M., Inoue M., Tatematsu M. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer. 1998 Jan 1;82(1):70–77. [PubMed] [Google Scholar]
  37. Zhang X. D., Coventry B. J., Jamieson G. G., Gill P. G. The utility of the proliferative index in pretreatment biopsy specimens of esophageal squamous cell carcinoma. Dis Esophagus. 1998 Oct;11(4):215–220. doi: 10.1093/dote/11.4.215. [DOI] [PubMed] [Google Scholar]
  38. van Triest B., Pinedo H. M., Blaauwgeers J. L., van Diest P. J., Schoenmakers P. S., Voorn D. A., Smid K., Hoekman K., Hoitsma H. F., Peters G. J. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res. 2000 Mar;6(3):1063–1072. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES